Free Trial

REGENXBIO (NASDAQ:RGNX) Receives "Buy" Rating from Chardan Capital

REGENXBIO logo with Medical background

Chardan Capital reissued their buy rating on shares of REGENXBIO (NASDAQ:RGNX - Free Report) in a research note published on Tuesday, Benzinga reports. They currently have a $52.00 price objective on the biotechnology company's stock.

Other equities research analysts have also recently issued research reports about the stock. Barclays reduced their target price on shares of REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. HC Wainwright reissued a "buy" rating and issued a $39.00 price target on shares of REGENXBIO in a research report on Wednesday, September 4th. StockNews.com raised shares of REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday, September 20th. Finally, Raymond James reissued an "outperform" rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $35.45.

Get Our Latest Stock Report on RGNX

REGENXBIO Trading Down 7.5 %

RGNX traded down $0.78 during trading on Tuesday, hitting $9.59. The stock had a trading volume of 486,680 shares, compared to its average volume of 598,876. REGENXBIO has a 12 month low of $9.11 and a 12 month high of $28.80. The company has a 50 day simple moving average of $11.26 and a 200-day simple moving average of $13.17. The firm has a market cap of $473.94 million, a PE ratio of -1.82 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The company had revenue of $22.30 million during the quarter, compared to analysts' expectations of $22.97 million. During the same period in the prior year, the company earned ($1.66) earnings per share. The business's quarterly revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that REGENXBIO will post -4.66 earnings per share for the current fiscal year.

Insider Transactions at REGENXBIO

In related news, Director Argeris N. Karabelas sold 11,000 shares of REGENXBIO stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the sale, the director now owns 11,286 shares of the company's stock, valued at approximately $169,741.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other REGENXBIO news, CEO Curran Simpson sold 9,648 shares of the business's stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $145,105.92. Following the completion of the sale, the chief executive officer now owns 170,137 shares of the company's stock, valued at $2,558,860.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Argeris N. Karabelas sold 11,000 shares of the business's stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $165,440.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company's stock, valued at $169,741.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,069 shares of company stock worth $833,602 in the last ninety days. Insiders own 13.13% of the company's stock.

Institutional Trading of REGENXBIO

A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. Vanguard Group Inc. increased its position in REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company's stock worth $102,756,000 after purchasing an additional 436,043 shares in the last quarter. Redmile Group LLC increased its position in REGENXBIO by 21.0% during the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company's stock worth $95,901,000 after purchasing an additional 790,866 shares in the last quarter. Integral Health Asset Management LLC increased its position in REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock worth $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Assenagon Asset Management S.A. increased its position in REGENXBIO by 258.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company's stock worth $9,552,000 after purchasing an additional 588,773 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in REGENXBIO by 9.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company's stock worth $3,972,000 after purchasing an additional 28,846 shares in the last quarter. Institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

See Also

Analyst Recommendations for REGENXBIO (NASDAQ:RGNX)

Should you invest $1,000 in REGENXBIO right now?

Before you consider REGENXBIO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.

While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines